Sudeep Paul - Jagsonpal Pharmaceuticals Vice Marketing
| JAGSNPHARM | 636.65 9.80 1.52% |
Executive
Sudeep Paul is Vice Marketing of Jagsonpal Pharmaceuticals Limited
| Address | Plot No. 412-415, Nimai Tower, Gurugram, India, 122015 |
| Phone | 91 12 4440 6710 |
| Web | https://www.jagsonpal.com |
Jagsonpal Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0605 % which means that it generated a profit of $0.0605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1326 %, meaning that it generated $0.1326 on every $100 dollars invested by stockholders. Jagsonpal Pharmaceuticals' management efficiency ratios could be used to measure how well Jagsonpal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Jagsonpal Pharmaceuticals' Non Currrent Assets Other are decreasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Other Current Assets is estimated to increase to about 381.4 M, while Total Assets are projected to decrease to under 1.7 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Pankaj Tewari | Bharti Airtel Limited | 52 | |
| Shashwat Sharma | Bharti Airtel Limited | N/A | |
| Amrita Padda | Bharti Airtel Limited | N/A | |
| Parag Rao | HDFC Bank Limited | 58 | |
| Venkatesh Raghavan | Bharti Airtel Limited | 51 | |
| Ravi Santhanam | HDFC Bank Limited | 54 | |
| Rakesh Rajput | HDFC Bank Limited | 54 | |
| Madhav Anchan | Tata Consultancy Services | N/A | |
| Kinshuk Gupta | Bharti Airtel Limited | N/A | |
| Hemen Modi | Reliance Industries Limited | N/A | |
| Ashima Bhat | HDFC Bank Limited | 53 | |
| Vidyut Gulati | Bharti Airtel Limited | 45 | |
| Anuj Khungar | Bharti Airtel Limited | 60 | |
| Vipul Shah | Reliance Industries Limited | N/A | |
| Yashaswin Sheth | Tata Consultancy Services | N/A | |
| Mukund Pendse | Reliance Industries Limited | N/A | |
| Jyoti Deshpande | Reliance Industries Limited | 54 | |
| Rohit Bansal | Reliance Industries Limited | N/A | |
| Sukanya BE | Tata Consultancy Services | 56 | |
| Nirav Shah | HDFC Bank Limited | 50 | |
| Soumen Ray | Bharti Airtel Limited | 51 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0605 |
Jagsonpal Pharmaceuticals Leadership Team
Elected by the shareholders, the Jagsonpal Pharmaceuticals' board of directors comprises two types of representatives: Jagsonpal Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jagsonpal. The board's role is to monitor Jagsonpal Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jagsonpal Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jagsonpal Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| S Rao, Chief Officer | ||
| Nandita Singh, Company Officer | ||
| Manish Gupta, MD Director | ||
| Abhishek Joshi, Company Officer | ||
| Bharat Chugh, Assistant Resources | ||
| Ashish Lakhotia, Chief Officer | ||
| Sudeep Paul, Vice Marketing |
Jagsonpal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jagsonpal Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0605 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 16.46 B | ||||
| Shares Outstanding | 26.55 M | ||||
| Shares Owned By Insiders | 76.28 % | ||||
| Shares Owned By Institutions | 1.47 % | ||||
| Price To Book | 8.71 X | ||||
| Price To Sales | 7.45 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Jagsonpal Stock
Jagsonpal Pharmaceuticals financial ratios help investors to determine whether Jagsonpal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jagsonpal with respect to the benefits of owning Jagsonpal Pharmaceuticals security.